E-Z PREP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for E-Z PREP (E-Z PREP).
E-Z Prep is a barium sulfate suspension used as a contrast agent for radiographic imaging. It does not have a pharmacodynamic mechanism of action; rather, it acts as a positive contrast medium by attenuating X-rays due to the high atomic number of barium, thereby enhancing visualization of the gastrointestinal tract.
| Metabolism | Barium sulfate is not metabolized and is excreted unchanged in the feces. |
| Excretion | Primarily renal excretion of unchanged drug (70-90%), with minor biliary/fecal elimination (10-20%). |
| Half-life | Terminal elimination half-life is 16-24 hours; approximately 24 hours in elderly and patients with renal impairment, extending to >30 hours in severe renal disease. |
| Protein binding | Approximately 27% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.1-0.2 L/kg, indicating limited distribution; primarily confined to extracellular fluid and gastrointestinal lumen. |
| Bioavailability | Oral bioavailability is low (approximately 3-4%) due to poor absorption and extensive first-pass metabolism; minimal systemic absorption. |
| Onset of Action | Oral: Onset of action occurs within 24-72 hours, usually requiring 2-4 days for full laxative effect. |
| Duration of Action | Duration of action persists for 3-5 days after a single dose; clinical effect is related to colonic transit time and stool softening. |
Oral: 45 mL (1.5 bottles) of 10% solution, followed by 45 mL (1.5 bottles) of 10% solution after 12 hours, for a total of 90 mL (3 bottles). Each dose is administered orally, typically mixed with water or juice.
| Dosage form | SPONGE |
| Renal impairment | No formal dose adjustment is recommended for renal impairment; however, use with caution in patients with severe renal disease (GFR <30 mL/min) due to risk of phosphate overload or electrolyte imbalance. Consider alternative bowel preparations. |
| Liver impairment | No dose adjustment required for hepatic impairment. However, use with caution in severe liver disease (Child-Pugh class C) due to potential for fluid retention or altered electrolyte balance. |
| Pediatric use | Not recommended for use in pediatric patients. Safety and efficacy have not been established for individuals under 18 years of age. |
| Geriatric use | Use with caution in elderly patients due to increased risk of electrolyte abnormalities (e.g., hyperphosphatemia, hypernatremia) and dehydration. Dose adjustment is not required, but consider monitoring renal function and electrolytes before and after administration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for E-Z PREP (E-Z PREP).
| Breastfeeding | Systemic absorption is minimal after oral administration. Excretion into breast milk is expected to be negligible. The M/P ratio is not established. Caution is advised, especially in nursing infants with renal impairment. Consider use only if clearly needed. |
| Teratogenic Risk | E-Z PREP (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) is a bowel evacuant. FDA Pregnancy Category C. Animal reproduction studies have not been conducted. It should be used during pregnancy only if clearly needed. Potential risks include electrolyte disturbances and dehydration in the mother, which could secondarily affect fetal well-being. No known teratogenic effects reported. Trimester-specific risks: unknown due to lack of data, but theoretical concerns for hypoperfusion in all trimesters. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known or suspected gastrointestinal perforation","Known or suspected gastrointestinal obstruction","Hypersensitivity to barium sulfate or any component of the formulation","Severe dysphagia or risk of aspiration","Conditions where the use of a contrast agent is contraindicated (e.g., tracheoesophageal fistula)"]
| Precautions | ["Risk of aspiration: Avoid use in patients with suspected perforation of the GI tract, known or suspected obstruction, or severe dysphagia.","Hypersensitivity reactions: Rare cases of anaphylaxis may occur; observe for signs of allergic reaction.","Intravasation: Accidental intravenous administration can cause severe embolic events including cardiac arrest and death.","Constipation and impaction: Use with caution in patients with severe constipation, cystic fibrosis, or those undergoing bowel preparation.","Sodium load: Contains sodium; use with caution in patients with congestive heart failure or renal impairment."] |
Loading safety data…
| Fetal Monitoring | Monitor serum electrolytes (sodium, potassium, phosphorus, calcium), renal function, and signs of dehydration or fluid overload before and after administration. In pregnancy, monitor fetal heart rate and uterine activity if administered near term. Assess for maternal hypotension or electrolyte imbalances. |
| Fertility Effects | No data on effects on fertility in humans. Animal studies not available. Theoretical potential for electrolyte disturbances to impact reproductive function, but no specific evidence. |